WuXi AppTec
WuXi AppTec Co Ltd is a China-based contract research, development, and manufacturing organization (CRDMO) serving the global pharmaceutical and biotechnology industries. The company operates an end-to-end service platform covering small molecule drug discovery, chemical synthesis, testing, advanced analytics, and manufacturing. Its operations are structured into five core business segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU (cell and gene therapy), and WuXi DDSU. Revenue is principally generated from fee-for-service research agreements and commercial manufacturing contracts with healthcare developers. Primary end markets comprise multinational pharmaceutical corporations, emerging biotechnology firms, and medical research institutes across North America, Europe, and Asia-Pacific. WuXi AppTec holds a dominant global market position in outsourced pharmaceutical R&D services and contract manufacturing. The company is headquartered in Shanghai, China, and maintains dual listings on the Shanghai Stock Exchange and the Stock Exchange of Hong Kong under ticker symbol 603259.
40 of the funds FundTelligence covers report a position in WuXi AppTec.
- Legal name
- WuXi AppTec Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 40
Funds holding WuXi AppTec
- Allianz Little Dragons — Allianz Global Investors · 3.51 % (largest positions only, September 2026)
- UBS Emerging Markets Sustainable Leaders Equity Fund — UBS · 3.3 % (largest positions only, September 2026)
- DWS Invest Chinese Equities — DWS · 3.11 % (full portfolio disclosed, June 2026)
- Schroder China Opportunities — Schroders · 2.67 % (largest positions only, October 2026)
- Janus Henderson Horizon China Opportunities Fund — Janus Henderson · 2.65 % (largest positions only, September 2026)
- Schroder ISF China — Schroders · 2.62 % (largest positions only, October 2026)
- Schroder ISF China A All Cap — Schroders · 2.35 % (full portfolio disclosed, June 2026)
- Lombard Odier Emerging High Conviction — Lombard Odier · 2.21 % (largest positions only, September 2026)
Showing the 8 largest of 40 funds holding it.